{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:07:35Z","timestamp":1794409655423,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bromodomain and extra-terminal (BET) proteins are epigenetic readers that can drive carcinogenesis and therapy resistance. RO6870810 is a novel, small-molecule BET inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a Phase 1 study of RO6870810 administered subcutaneously for 21 or 14 days of 28- or 21-day cycles, respectively, in patients with the nuclear protein of the testis carcinoma (NC), other solid tumours, or diffuse large B-cell lymphoma (DLBCL) with MYC deregulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fatigue (42%), decreased appetite (35%) and injection-site erythema (35%) were the most common treatment-related adverse events. Pharmacokinetic parameters demonstrated linearity over the dose range tested and support once-daily dosing. Pharmacodynamic assessments demonstrated sustained decreases in CD11b levels in peripheral blood mononuclear cells. Objective response rates were 25% (2\/8), 2% (1\/47) and 11% (2\/19) for patients with NC, other solid tumours and DLBCL, respectively. Responding tumours had evidence of deregulated MYC expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This trial establishes the safety, favourable pharmacokinetics, evidence of target engagement and preliminary single-agent activity of RO6870810. Responses in patients with NC, other solid tumours and DLBCL provide proof-of-principle for BET inhibition in\n                      <jats:italic>MYC<\/jats:italic>\n                      -driven cancers. The results support further exploration of RO6870810 as monotherapy and in combinations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trials registration<\/jats:title>\n                    <jats:p>NCT01987362.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-020-01180-1","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T21:02:19Z","timestamp":1607893339000},"page":"744-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-4095","authenticated-orcid":false,"given":"Geoffrey I.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh","family":"T. Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Weise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Paul","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Labriola-Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Boisserie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Pierceall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Passe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"DeMario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kornacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"1180_CR1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides, T. Chromatin modifications and their function. Cell 128, 693\u2013705 (2007).","journal-title":"Cell"},{"key":"1180_CR2","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.bbapap.2016.06.007","volume":"1864","author":"A Drazic","year":"2016","unstructured":"Drazic, A., Myklebust, L. M., Ree, R. & Arnesen, T. The world of protein acetylation. Biochim Biophys. Acta 1864, 1372\u20131401 (2016).","journal-title":"Biochim Biophys. Acta"},{"key":"1180_CR3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0014-5793(01)03309-9","volume":"513","author":"L Zeng","year":"2002","unstructured":"Zeng, L. & Zhou, M. M. Bromodomain: an acetyl-lysine binding domain. FEBS Lett. 513, 124\u2013128 (2002).","journal-title":"FEBS Lett."},{"key":"1180_CR4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","volume":"12","author":"M Perez-Salvia","year":"2017","unstructured":"Perez-Salvia, M. & Esteller, M. Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics 12, 323\u2013339 (2017).","journal-title":"Epigenetics"},{"key":"1180_CR5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O. et al. Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"1180_CR6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tibs.2015.06.002","volume":"40","author":"CY Wang","year":"2015","unstructured":"Wang, C. Y. & Filippakopoulos, P. Beating the odds: BETs in disease. Trends Biochem. Sci. 40, 468\u2013479 (2015).","journal-title":"Trends Biochem. Sci."},{"key":"1180_CR7","doi-asserted-by":"crossref","first-page":"53997","DOI":"10.18632\/oncotarget.9804","volume":"7","author":"V Sahai","year":"2016","unstructured":"Sahai, V., Redig, A. J., Collier, K. A., Eckerdt, F. D. & Munshi, H. G. Targeting BET bromodomain proteins in solid tumors. Oncotarget 7, 53997\u201354009 (2016).","journal-title":"Oncotarget"},{"key":"1180_CR8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drudis.2017.09.011","volume":"23","author":"M Ramadoss","year":"2018","unstructured":"Ramadoss, M. & Mahadevan, V. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. Drug Discov. Today 23, 76\u201389 (2018).","journal-title":"Drug Discov. Today"},{"key":"1180_CR9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M. et al. BET bromodomain inhibition as a therapeutic strategy to target c-myc. Cell 146, 904\u2013917 (2011).","journal-title":"Cell"},{"key":"1180_CR10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2017.02.021","volume":"394","author":"AS Leal","year":"2017","unstructured":"Leal, A. S., Williams, C. R., Royce, D. B., Pioli, P. A., Sporn, M. B. & Liby, K. T. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Lett. 394, 76\u201387 (2017).","journal-title":"Cancer Lett."},{"key":"1180_CR11","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","volume":"111","author":"M Ceribelli","year":"2014","unstructured":"Ceribelli, M., Kelly, P. N., Shaffer, A. L., Wright, G. W., Xiao, W., Yang, Y. et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc. Natl Acad. Sci. USA 111, 11365\u201311370 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1180_CR12","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","volume":"16","author":"H Zhu","year":"2016","unstructured":"Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J. et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 16, 2829\u20132837 (2016).","journal-title":"Cell Rep."},{"key":"1180_CR13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","volume":"18","author":"SJ Hogg","year":"2017","unstructured":"Hogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A. et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 18, 2162\u20132174 (2017).","journal-title":"Cell Rep."},{"key":"1180_CR14","doi-asserted-by":"crossref","first-page":"21609","DOI":"10.18632\/oncotarget.15450","volume":"8","author":"M Cioffi","year":"2017","unstructured":"Cioffi, M., Trabulo, S. M., Vallespinos, M., Raj, D., Kheir, T. B., Lin, M. L. et al. The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget 8, 21609\u201321625 (2017).","journal-title":"Oncotarget"},{"key":"1180_CR15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","volume":"24","author":"B Chapuy","year":"2013","unstructured":"Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G., Qi, J. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777\u2013790 (2013).","journal-title":"Cancer Cell"},{"key":"1180_CR16","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","volume":"27","author":"CA French","year":"2008","unstructured":"French, C. A., Ramirez, C. L., Kolmakova, J., Hickman, T. T., Cameron, M. J., Thyne, M. E. et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27, 2237\u20132242 (2008).","journal-title":"Oncogene"},{"key":"1180_CR17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/2159-8290.CD-14-0014","volume":"4","author":"CA French","year":"2014","unstructured":"French, C. A., Rahman, S., Walsh, E. M., Kuhnle, S., Grayson, A. R., Lemieux, M. E. et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov. 4, 928\u2013941 (2014).","journal-title":"Cancer Discov."},{"key":"1180_CR18","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/onc.2013.126","volume":"33","author":"AR Grayson","year":"2014","unstructured":"Grayson, A. R., Walsh, E. M., Cameron, M. J., Godec, J., Ashworth, T., Ambrose, J. M. et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene 33, 1736\u20131742 (2014).","journal-title":"Oncogene"},{"key":"1180_CR19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","volume":"21","author":"M Boi","year":"2015","unstructured":"Boi, M., Gaudio, E., Bonetti, P., Kwee, I., Bernasconi, E., Tarantelli, C. et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin. Cancer Res. 21, 1628\u20131638 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1180_CR20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","volume":"21","author":"SE Trabucco","year":"2015","unstructured":"Trabucco, S. E., Gerstein, R. M., Evens, A. M., Bradner, J. E., Shultz, L. D., Greiner, D. L. et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin. Cancer Res. 21, 113\u2013122 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1180_CR21","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","volume":"114","author":"KJ Savage","year":"2009","unstructured":"Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P. et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114, 3533\u20133537 (2009).","journal-title":"Blood"},{"key":"1180_CR22","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green, T. M., Young, K. H., Visco, C., Xu-Monette, Z. Y., Orazi, A., Go, R. S. et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30, 3460\u20133467 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1180_CR23","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3324\/haematol.2018.191684","volume":"103","author":"AA Mensah","year":"2018","unstructured":"Mensah, A. A., Cascione, L., Gaudio, E., Tarantelli, C., Bomben, R., Bernasconi, E. et al. Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. Haematologica 103, 2049\u20132058 (2018).","journal-title":"Haematologica"},{"key":"1180_CR24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1180_CR25","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E. et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1180_CR26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","volume":"8","author":"A Stathis","year":"2018","unstructured":"Stathis, A. & Bertoni, F. BET proteins as targets for anticancer treatment. Cancer Discov. 8, 24\u201336 (2018).","journal-title":"Cancer Discov."},{"key":"1180_CR27","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","volume":"28","author":"DB Doroshow","year":"2017","unstructured":"Doroshow, D. B., Eder, J. P. & LoRusso, P. M. BET inhibitors: a novel epigenetic approach. Ann. Oncol. 28, 1776\u20131787 (2017).","journal-title":"Ann. Oncol."},{"key":"1180_CR28","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","volume":"3","author":"S Amorim","year":"2016","unstructured":"Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X. et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 3, e196\u2013e204 (2016).","journal-title":"Lancet Haematol."},{"key":"1180_CR29","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","volume":"3","author":"C Berthon","year":"2016","unstructured":"Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez-Roca, C., Yee, K. et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 3, e186\u2013e195 (2016).","journal-title":"Lancet Haematol."},{"key":"1180_CR30","doi-asserted-by":"crossref","first-page":"iii7","DOI":"10.1093\/annonc\/mdy048","volume":"29","author":"KA Blum","year":"2018","unstructured":"Blum, K. A., Abramson, J., Maris, M., Flinn, I., Goy, A., Mertz, J. et al. A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma. Ann. Oncol. 29, iii7\u2013iii9 (2018).","journal-title":"Ann. Oncol."},{"key":"1180_CR31","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","volume":"36","author":"J Lewin","year":"2018","unstructured":"Lewin, J., Soria, J. C., Stathis, A., Delord, J. P., Peters, S., Awada, A. et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J. Clin. Oncol. 36, 3007\u20133014 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1180_CR32","doi-asserted-by":"crossref","unstructured":"Piha-Paul, S. A., Hann, C. L., French, C. A., Cousin, S., Brana, I., Cassier, P. A. et al. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Cancer Spectrum 4, pkz093 (2019).","DOI":"10.1093\/jncics\/pkz093"},{"key":"1180_CR33","doi-asserted-by":"crossref","first-page":"(abstract 2504)","DOI":"10.1200\/JCO.2017.77.4174","volume":"36","author":"PG Aftimos","year":"2018","unstructured":"Aftimos, P. G., Bechter, O., Awada, A., Jungels, C., Dumez, H., Huyvaert, N. et al. Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (pts) with advanced solid tumors. J. Clin. Oncol. 36, (abstract 2504) (2018).","journal-title":"J. Clin. Oncol."},{"key":"1180_CR34","first-page":"abstr. 4110","volume":"29","author":"J Hilton","year":"2018","unstructured":"Hilton, J., Cristea, M. C., Voskoboynik, M., Postel-Vinay, S., Edenfield, W., Gavai, A. et al. Initial results from a phase I\/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer. Ann. Oncol. 29, abstr. 4110 (2018).","journal-title":"Ann. Oncol."},{"key":"1180_CR35","doi-asserted-by":"crossref","first-page":"138687","DOI":"10.1172\/jci.insight.138687","volume":"5","author":"A Antolic","year":"2020","unstructured":"Antolic, A., Wakimoto, H., Jiao, Z., Gorham, J. M., DePalma, S. R., Lemieux, M. E. et al. BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. JCI Insight 5, 138687 (2020).","journal-title":"JCI Insight"},{"key":"1180_CR36","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/ijms20071527","volume":"20","author":"J Piquereau","year":"2019","unstructured":"Piquereau, J., Boet, A., P\u00e9choux, C., Antigny, F., Lambert, M., Gressette, M. et al. The BET bromodomain inhibitor I-BET-151 induces structural and functional alterations of the heart mitochondria in healthy male mice and rats. Int. J. Mol. Sci. 20, 1527 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1180_CR37","doi-asserted-by":"crossref","first-page":"abstract 6085","DOI":"10.1200\/JCO.2018.36.15_suppl.6085","volume":"36","author":"NG Chau","year":"2018","unstructured":"Chau, N. G., Ma, C., Danga, K., Al-Sayegh, H., Sridharan, M., Nardi, V. et al. A novel prognostic risk classification model for NUT midline carcinoma: a largest cohort analysis from the NMC registry. J. Clin. Oncol. 36, abstract 6085 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1180_CR38","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","volume":"124","author":"AM Petrich","year":"2014","unstructured":"Petrich, A. M., Gandhi, M., Jovanovic, B., Castillo, J. J., Rajguru, S., Yang, D. T. et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 124, 2354\u20132361 (2014).","journal-title":"Blood"},{"key":"1180_CR39","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S. et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30, 3452\u20132459 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1180_CR40","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679\u2013690 (2018).","journal-title":"Nat. Med."},{"key":"1180_CR41","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong, C. Y., Gilan, O., Lam, E. Y., Rubin, A. F., Ftouni, S., Tyler, D. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538\u2013542 (2015).","journal-title":"Nature"},{"key":"1180_CR42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature14898","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J. S., Muhar, M. et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525, 543\u2013547 (2015).","journal-title":"Nature"},{"key":"1180_CR43","volume":"5","author":"K Kumar","year":"2015","unstructured":"Kumar, K., Raza, S. S., Knab, L. M., Chow, C. R., Kwok, B., Bentrem, D. J. et al. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci. Rep. 5, 9489 (2015).","journal-title":"Sci. Rep."},{"key":"1180_CR44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M. et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529, 413\u2013417 (2016).","journal-title":"Nature"},{"key":"1180_CR45","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.celrep.2016.06.091","volume":"16","author":"AM Kurimchak","year":"2016","unstructured":"Kurimchak, A. M., Shelton, C., Duncan, K. E., Johnson, K. J., Brown, J., O\u2019Brien, S. et al. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep. 16, 1273\u20131286 (2016).","journal-title":"Cell Rep."},{"key":"1180_CR46","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1158\/1078-0432.CCR-16-0453","volume":"23","author":"Y Ma","year":"2017","unstructured":"Ma, Y., Wang, L., Neitzel, L. R., Loganathan, S. N., Tang, N., Qin, L. et al. The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer. Clin. Cancer Res. 23, 2027\u20132037 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1180_CR47","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1158\/1078-0432.CCR-16-1903","volume":"23","author":"JE Jang","year":"2017","unstructured":"Jang, J. E., Eom, J. I., Jeung, H. K., Cheong, J. W., Lee, J. Y., Kim, J. S. et al. AMPK-ULK1-mediated autophagy confers resistance to BET inhibitor JQ1 in acute myeloid leukemia stem cells. Clin. Cancer Res. 23, 2781\u20132794 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1180_CR48","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.celrep.2016.07.032","volume":"16","author":"Y Zhao","year":"2016","unstructured":"Zhao, Y., Liu, Q., Acharya, P., Stengel, K. R., Sheng, Q., Zhou, X. et al. High-resolution mapping of RNA polymerases identifies mechanisms of sensitivity and resistance to BET inhibitors in t(8;21) AML. Cell Rep. 16, 2003\u20132016 (2016).","journal-title":"Cell Rep."},{"key":"1180_CR49","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-15-0924","volume":"15","author":"SJ Hogg","year":"2016","unstructured":"Hogg, S. J., Newbold, A., Vervoort, S. J., Cluse, L. A., Martin, B. P., Gregory, G. P. et al. BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members. Mol. Cancer Ther. 15, 2030\u20132041 (2016).","journal-title":"Mol. Cancer Ther."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-01180-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-01180-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-01180-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:07:12Z","timestamp":1684602432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01180-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2,16]]}},"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01180-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]},"assertion":[{"value":"24 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was done in accordance with the International Conference on Harmonization for Good Clinical Practice and the Declaration of Helsinki. The study protocol was approved by institutional review boards at each study site (Western Institutional Review Board, Puyallup, WA; Dana-Faber Cancer Institute Institutional Review Board, Boston, MA; University Hospitals Institutional Review Board, Cleveland, OH). Written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent prior to study initiation. Per the Informed Consent Form, this included consent for reporting or publication of data resulting from the study provided patients are not identified by name. No identifying patient details or images are used in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Qualified researchers may request access to individual patient level data through the clinical study data request platform (\n                      \n                      ). Further details on Roche's criteria for eligible studies are available here (\n                      \n                      ). For further details on Roche\u2019s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All authors have received grants and non-financial or other support from F. Hoffmann-La Roche during the conduct of the study. Editorial support, funded by the sponsor, was provided by an independent medical writer under the guidance of the authors. G.I.S. has served on advisory boards for Roche, Lilly, Pfizer, Bicycle Pharmaceuticals, Merck\/EMD Serono, Sierra Oncology, G1 Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Bayer, Ipsen, Astex and Almac and has received sponsored research funding from Lilly, Pfizer, Array BioPharma, Merck, Merck\/EMD Serono and Sierra Oncology. P.L. has participated in data safety monitoring boards from Chiltern, Agios, Five Prime, Parexel, Halozyme, Novella Clinical and Tyme and in advisory boards from Alexion, Ariad, CytomX, Roche\/Genentech, GenMab, Glenmark, Ignyta, Menarini, Novartis, Omniox and Takeda. K.T.D. has participated in advisory boards for QED Therapeutics and Seattle Genetics. C.A.J. has received honorarium or consulting fees from Kite Pharma, Precision Biosciences, Pfizer, Bayer, Novartis, Celgene and Humanigen. U.V. has received research grants from Bristol Myers Squibb, Astellas and Pfizer and personal fees from Bayer, Bristol Myers Squibb, Astellas and Pfizer. A.W. has participated in a speaker bureau and advisory board for Array BioPharma. P.F.C. has received research funding from Roche\/Genentech and ADC Therapeutics and participated in speaker bureaus from Celgene and advisory boards for Kite Pharma, Genentech, and Fate Therapeutics. C.A.F. has received research grants from National Institutes of Health, GlaxoSmithKline, C4 Therapeutics, Curis and Constellation and personal fees from GlaxoSmithKline. E.L.-T. and M.D. were employees of Roche at the time of the study and have Roche stock. F.B., W.E.P., J.Z., and S.P. were employees of Roche at the time of the study. M.K. is an employee of Roche and has Roche stock. P.A. has consulted for Merck, Bristol Myers Squibb, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, and Tessa and received institutional research funding from Merck, Bristol Myers Squibb, Affimed, Adaptive, Roche, Tensha, Otsuka, Sigma Tau, Genentech and IGM. The following authors have nothing additional to disclose beyond the support received for this work: A.D. and J.P.E.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was funded by F. Hoffmann-La Roche, Ltd.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}